Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer

Prostate cancer is the most common cancer among men and the second leading cause of cancer-related deaths in men in the United States. The treatment paradigm for prostate cancer has evolved with the emergence of a variety of novel therapies which have improved survival; however, treatment-related to...

Descripción completa

Detalles Bibliográficos
Autores principales: Zarrabi, Kevin K., Narayan, Vivek, Mille, Patrick J., Zibelman, Matthew R., Miron, Benjamin, Bashir, Babar, Kelly, William Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Advances in Prostate Cancer Diagnostics, Treatments and Outcomes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10285603/
https://www.ncbi.nlm.nih.gov/pubmed/37359737
http://dx.doi.org/10.1177/17562872231182219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10285603/
https://www.ncbi.nlm.nih.gov/pubmed/37359737
http://dx.doi.org/10.1177/17562872231182219

Ejemplares similares